Details

Autor(en) / Beteiligte

• GRÖSCHEL, Stefan
• SCHLENK, Richard F
• GERMING, Ulrich
• SCHMIDT-WOLF, Ingo G. H
• BERNA BEVERLOO, H
• SCHUURHUIS, Gerrit J
• OSSENKOPPELE, Gert J
• SCHLEGELBERGER, Brigitte
• VERDONCK, Leo F
• VELLENGA, Edo
• VERHOEF, Gregor
• VANDENBERGHE, Peter
• ENGELMANN, Jan
• PABST, Thomas
• BARGETZI, Mario
• KRAUTER, Jürgen
• GANSER, Arnold
• VALK, Peter J. M
• LÖWENBERG, Bob
• DÖHNER, Konstanze
• DÖHNER, Hartmut
• DELWEL, Ruud
• ROCKOVA, Veronika
• TELEANU, Veronica
• KÜHN, Michael W. M
• EIWEN, Karina
• ERPELINCK, Claudia
• HAVERMANS, Marije
• LÜBBERT, Michael

Titel

Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

Ist Teil von

• Journal of clinical oncology, 2013-01, Vol.31 (1), p.95-103

Ort / Verlag

Alexandria, VA: American Society of Clinical Oncology

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group prospective treatment trials. Material was available from 177 AML patients for EVI1 expression analysis. We divided 286 MLL-rearranged AMLs into three subgroups: t(9;11)(p22;q23) (44.8%), t(6;11)(q27;q23) (14.7%), and t(v;11q23) (40.5%). EVI1 overexpression (EVI1(+)) was found in 45.8% of all patients with t(11q23), with t(6;11) showing the highest frequency (83.9%), followed by t(9;11) at 40.0%, and t(v;11q23) at 34.8%. Concurrent gene mutations were rare or absent in all three subgroups. Within all t(11q23) AMLs, EVI1(+) was the sole prognostic factor, predicting for inferior overall survival (OS; hazard ratio [HR], 2.06; P = .003), relapse-free survival (HR, 2.28; P = .002), and event-free survival (HR, 1.79; P = .009). EVI1(+) AMLs with t(11q23) in first complete remission (CR) had a significantly better outcome after allogeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-Byar, P = .0006). EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001). Among t(9;11) AMLs, EVI1(+) again was the sole independent adverse prognostic factor for survival. Deregulated EVI1 expression defines poor prognostic subsets among AML with t(11q23) and AML with t(9;11)(p22;q23). Patients with EVI1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR.